Clinical Trial

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
Protocol Amendment History 8 changes
notable Trial sites expanded: 17 -> 22 locations 2026-06-03
critical Primary endpoint(s) modified 2026-05-20
notable Enrollment increased: 80 -> 240 participants 2026-05-20
minor Trial arms changed: 3 -> 4 2026-05-20
notable Primary completion pushed: 2028-11 -> 2030-05 2026-05-20
minor Completion pushed: 2029-01 -> 2030-07 2026-05-20
notable Trial sites expanded: 10 -> 17 locations 2026-04-23
notable Trial sites expanded: 6 -> 10 locations 2026-04-02
Trial Details
NCT Number NCT07449702
Lead Sponsor Oruka Therapeutics, Inc.
Conditions Plaque Psoriasis
Enrollment 240 participants
Start Date 2026-02-23
Primary Completion 2030-05 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-05